Literature DB >> 22803571

Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas.

Tetsuo Ushiku1, Aya Shinozaki-Ushiku, Daichi Maeda, Shigeki Morita, Masashi Fukayama.   

Abstract

AIMS: This study aimed to clarify claudin-6 expression patterns in cancers. METHODS AND
RESULTS: We surveyed claudin-6 expression by immunohistochemistry using tissue microarray in 860 tumours, including germ cell tumours and major carcinomas. Claudin-6 was expressed consistently in germ cell tumours (28 of 28, 100%), whereas only 64 (8%) of 832 non-germ cell tumours demonstrated claudin-6 expression. Further immunohistochemical study in full tissue sections demonstrated diffuse claudin-6 staining in all seminomas (n=14), embryonal carcinomas (n=10), yolk sac tumours (n=12) and mononuclear trophoblastic cells of choriocarcinomas (n=3), and focal staining in immature epithelial components of immature teratomas (n=6). Additionally, because alpha-fetoprotein (AFP)-producing gastric adenocarcinomas and pulmonary high-grade fetal adenocarcinomas were among the claudin-6 expressing non-germ cell tumours in the microarray studies, we predicted that claudin-6 may be a biomarker for them and studied additional tumours in full sections, which showed claudin-6 expression in AFP-producing gastric adenocarcinomas (18 of 20, 90%) and pulmonary high-grade fetal adenocarcinomas (four of five, 80%). Only one of 11 hepatoblastomas demonstrated focal claudin-6 staining.
CONCLUSIONS: This study demonstrated that claudin-6 is a novel diagnostic marker for primitive germ cell tumours and is also expressed frequently in some cancers with a primitive phenotype.
© 2012 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22803571     DOI: 10.1111/j.1365-2559.2012.04314.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  16 in total

1.  Metastatic seminomas in lymph nodes: CD10 immunoreactivity can be a pitfall of differential diagnosis.

Authors:  Yasunori Ota; Kuniko Iihara; Tomiko Ryu; Teppei Morikawa; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

2.  Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.

Authors:  Weiwei Weng; Meng Zhang; Shujuan Ni; Cong Tan; Midie Xu; Xin Wang; Hui Sun; Lei Wang; Dan Huang; Weiqi Sheng
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Claudin-6 increases SNAI1, NANOG and SOX2 gene expression in human gastric adenocarcinoma AGS cells.

Authors:  Priscila Anhel Medrano-Gonzálezl; Franklin Cruz-Villegas; Alejandro Alarcón Del Carmen; Luis Felipe Montaño; Erika Patricia Rendón-Huerta
Journal:  Mol Biol Rep       Date:  2022-09-28       Impact factor: 2.742

Review 4.  Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.

Authors:  Baixin Ye; Yongxian Hu; Mingming Zhang; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

Review 5.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

6.  Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer.

Authors:  Tomohiro Kohmoto; Kiyoshi Masuda; Katsutoshi Shoda; Rizu Takahashi; Sae Ujiro; Shoichiro Tange; Daisuke Ichikawa; Eigo Otsuji; Issei Imoto
Journal:  Gastric Cancer       Date:  2019-10-25       Impact factor: 7.370

7.  Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.

Authors:  Stefan Hutzler; Stephanie Erbar; Robert A Jabulowsky; Jan R H Hanauer; Jürgen H Schnotz; Tim Beissert; Bianca S Bodmer; Regina Eberle; Klaus Boller; Thorsten Klamp; Ugur Sahin; Michael D Mühlebach
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

Review 8.  Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells.

Authors:  Kenly Wuputra; Chia-Chen Ku; Deng-Chyang Wu; Ying-Chu Lin; Shigeo Saito; Kazunari K Yokoyama
Journal:  J Exp Clin Cancer Res       Date:  2020-06-03

9.  Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer.

Authors:  Qiang Wang; Yan Zhang; Tao Zhang; Zhi-Gang Han; Li Shan
Journal:  Onco Targets Ther       Date:  2015-07-31       Impact factor: 4.147

10.  Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6.

Authors:  Christiane R Stadler; Hayat Bähr-Mahmud; Laura M Plum; Kathrin Schmoldt; Anne C Kölsch; Özlem Türeci; Ugur Sahin
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.